Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $14.2 million.

  • Coeptis Therapeutics Holdings' Liabilities and Shareholders Equity rose 5834.82% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year increase of 11261.73%. This contributed to the annual value of $8.9 million for FY2024, which is 9489.14% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Liabilities and Shareholders Equity of $14.2 million as of Q3 2025, which was up 5834.82% from $12.2 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Liabilities and Shareholders Equity's 5-year high stood at $76.6 million during Q1 2021, with a 5-year trough of $4.6 million in Q4 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $10.8 million (2024), whereas its average is $26.6 million.
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' Liabilities and Shareholders Equity tumbled by 9217.94% in 2023 and then surged by 9489.14% in 2024.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Liabilities and Shareholders Equity (Quarter) stood at $6.8 million in 2021, then increased by 17.0% to $7.9 million in 2022, then tumbled by 42.25% to $4.6 million in 2023, then surged by 94.89% to $8.9 million in 2024, then soared by 59.19% to $14.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $14.2 million in Q3 2025, compared to $12.2 million in Q2 2025 and $13.5 million in Q1 2025.